Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2014 Authors' conclusions At present, the evidence base for the use of Oncotype DX in the population of early invasive breast cancer that is ER+, HER2-, and LN+ for guiding treatment decisions in the adjuvant setting is very limited and further restricted to women. Guidelines on the use of Oncotype DX in clinical practice were limited to a few general statements about molecular testing. Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Breast Neoplasms, Male; Gene Expression Profiling; Humans Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000832 Date abstract record published 17/07/2014 |